UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
24 sept. 2024 08h00 HE
|
Unity Biotechnology, Inc.
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
21 juin 2023 07h00 HE
|
Unity Biotechnology, Inc.
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel...
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
14 févr. 2022 08h00 HE
|
Unity Biotechnology, Inc.
24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
21 avr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
23 mars 2021 16h01 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
26 févr. 2021 16h05 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
24 févr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
08 févr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY...
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
01 févr. 2021 08h00 HE
|
Unity Biotechnology, Inc.
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz,...
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
15 sept. 2020 08h00 HE
|
Unity Biotechnology, Inc.
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...